Company intelligence / Profile preview

Monopo

Wilmette, Illinois, United Statesmonopo.nyc ↗

Ownership: Private
Employees: ~15
Development stage: Other

Overview

Monopar Therapeutics has multiple clinical and preclinical programs. Its lead asset for Wilson Disease, ALXN1840, has completed Phase 3. Its radiopharmaceuticals for advanced solid tumors are in early clinical or late preclinical stages. No approved products yet[1][3].

Therapeutic areas: Rare DiseasesOncology
Modalities: Radiopharmaceutical (for oncology programs)Small molecule (for Wilson Disease program)
Industry: Biotech

Partnerships

None specifically listed in public sources as of June 2025.

Beyond the preview

Go deeper on Monopo.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Monopo.

Explore the full profile